Using rTMS with AI to help children with dyslexia improve reading skills

Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) as an Adjunct to AI Enabled Remedial Intervention in School Going Children (Aged 6-18 Years) Having Specific Learning Disorder With Dyslexia

Not applicable Interventional All India Institute of Medical Sciences, New Delhi · NCT05923645

This study is testing if using a special brain treatment along with an AI program can help children with dyslexia improve their reading skills better than regular methods.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment60 (estimated)
Ages6 Years to 18 Years
SexAll
SponsorAll India Institute of Medical Sciences, New Delhi Academic / other
Locations1 site (Delhi)
Trial IDNCT05923645 on ClinicalTrials.gov

What this trial studies

This study investigates the effectiveness of high-frequency repetitive Transcranial Magnetic Stimulation (Hf rTMS) as an adjunct to an AI-enabled remedial intervention for children diagnosed with dyslexia. The trial will involve screening school-aged children who meet the DSM-5 criteria for specific learning disorder (SLD) with dyslexia, followed by a structured intervention combining AI-based phonological training and rTMS over six weeks. Participants will undergo baseline assessments, including neuroimaging for a subset, to evaluate their reading abilities before and after the intervention. The goal is to determine if this combined approach can enhance reading skills more effectively than traditional methods alone.

Who should consider this trial

Good fit: Ideal candidates are Indian school-aged children between 6-18 years old diagnosed with dyslexia and whose parents are willing to participate.

Not a fit: Patients who have received remedial intervention within the last 12 weeks or have other neurological or psychiatric disorders may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could significantly improve reading abilities in children with dyslexia, offering a new avenue for treatment.

How similar studies have performed: Previous studies have shown promising results with neuromodulation techniques like rTMS in treating learning disorders, suggesting potential for success in this novel combination approach.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Indian school going children aged 6-18 years having specific learning disorder (SLD) with dyslexia diagnosed by DSM-5 criteria
* English as one of the languages in school
* Parents willing for the study

Exclusion Criteria:

* Parents not willing to participate or follow up at desired frequency of study
* Child who has already received or is on remedial intervention within last 12 weeks provided by Child Psychologist/ Clinician/Psychiatrist
* Children who participated in a completed DM dissertation on remedial program in SLD
* Child already on any psychotropic medications
* Neurological or psychiatric disorder other than comorbid disorders of SLD
* Uncontrolled epilepsy as defined by seizure frequency \>1/month for preceding 3 months
* Severe concurrent illness or disease or unstable medical conditions
* Any contraindications for MRI like presence of pacemaker, metallic implant
* Any contraindications for TMS like Implanted electronic device and non-removable metallic objects near coil e.g. pacemaker, cochlear implant; presence of ferromagnetic metal in the head outside the mouth; on medication lowering seizure threshold.

Where this trial is running

Delhi

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions DyslexiaSpecific Learning DisabilityTranscranial Magnetic StimulationSLDTMSHf rTMS
Last reviewed 2026-06-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.